Delving into the Dry - Eye Pipeline

After years of fi ts and starts, the often stalled but always prodigious machinery of the dryeye pipeline appears to be moving forward. Thanks to improvements in designing clinical trials, monitoring patients’ signs and symptoms and evaluating the performance of therapeutic agents, a number of drugs are making their way through the clinical trial process. These agents include new mucomimetics, receptor inhibitors and anti-infl ammatories. Here’s a comprehensive look at the dry-eye drugs you may be using in the coming years.